Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Amgen, Inc
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis
To establish a dose-response efficacy profile of AMG 827 compared with placebo as measured by the percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at week 12 and to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A randomised active controlled study of AMG 162 in breast cancer subjects with bone metastases who have not previously been treated with bisphosphonate therapy
To evaluate the effect of different doses and schedules of AMG 162 on the percent change from baseline in urinary N-telopeptide (uNTx) at week 13
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Multicenter, Double-blind, Placebo-controlled Roll-over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer
To evaluate the safety of darbepoetin alfa beyond 16 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment with Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Density
The primary objective of the study is to estimate the effect of denosumab (AMG 162), compared to placebo on cortical thickness at the distal radius, as determined by in-vivo microCT (XtremeCT®) at 12 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Long-term Assessment of Safety and Physical Function with AMG 108 Subcutaneous Monthly Treatment in Subjects with Rheumatoid Arthritis
The primary objective for this study is to assess long-term safety of AMG 108 (125mg, 250 mg) SC in subjects with RA previously enrolled in study 20050168
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
An Open Label Treatment Extension Study of AMG706
To provide ongoing treatment with AMG 706 monotherapy for those subjects who have completed the planned duration of treatment with AMG 706 on a separate Amgen protocol and demonstrate continuing clini...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Study to assess the safety, tolerability and efficacy of AMG 145 in patients with heterozygous familial hypercholesterolemia
To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 every-2-weeks (Q2W) and monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Study to evaluate the effect of AMG 747 on schizophrenia negative symptoms (20110165)
To evaluate the treatment effect of AMG 747 compared to placebo on negative symptoms as measured by the Negative Symptom Assessment Scale (NSA-16) in patients with schizophrenia stabilized with ongoin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Study of the effects of blocking the enzyme PCSK9 on artery wall inflamation
To evaluate the effect of evolocumab on arterial wall inflammation, as measured by percent change from baseline in target-to-background ratio of an index vessel by FDG-PET/CT at week 16 in subjects wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s Disease
To evaluate the safety of long-term exposure with AMG 827 in subjects with Crohn’s disease
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
11
12
Suivant